
Overview
Status
Active
Registry date
2017-09-20
Share capital
50,000.00 PLN
Registered address
ul. Marynarska 21, 02-674 Warszawa, Poland
Website
Email
Phone
Financials
Revenue history (in k)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 741 days for 2022).
- 202503/07/2026
- 202418/09/2025
- 202325/07/2025
- 202225/07/2025
- 202130/09/2022
- 202030/09/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.25mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD -153.11kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 1.35mMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 471.28kMedianUSD 608.93kAverageUSD 11.85m
Industry
Offer
- Hyaluronic acid injectable gel
- Joint food supplement
Website technology
- Website
- WordPress
- Analytics and marketing
- Google Analytics
- Hotjar
Authorized Representatives
Sylvain Ducret – President of the Management Board
Manner of representation
Each member of the management board is authorised to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Aptissen Sa | 1,000 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-08-26.
45 1940 1210 0103 6578 0010 0000
93 1940 1210 0103 6578 0011 0000
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 6, 2021 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| New Nordic Healthbrands Polskasp. z o.o. | $1,677,813.61 | newnordic.pl | ||
| Farmedicasp. z o.o. | $1,689,796.86 | farmedica.pl | ||
| Phytopur Biosp. z o.o. | $1,672,156.55 | phytopurbio.pl | ||
| DEEP Pharmasp. z o.o. | $1,664,192.79 | deeppharma.pl | ||
| Alpen Pharma Polskasp. z o.o. | $1,465,675.63 | alpenpharma.pl | ||
| Dermaprofilsp. z o.o. | $1,431,262.08 | dermaprofil.pl | ||
| Atradis Polskasp. z o.o. | $1,284,064.17 | atradis.pl | ||
| Sepharmasp. z o.o. | $1,263,307.80 | sepharma.pl | ||
| Eickemeyer - Veterinary Technology for Lifesp. z o.o. | $1,238,702.38 | eickemeyer.pl | ||
| Mana Medicalsp. z o.o. | $1,210,831.22 | manamedical.pl |
Change history
| Date | Event | |
|---|---|---|
| 2021-08-27 | Share capital increase (5,000.00 PLN → 50,000.00 PLN) | |
| 2019-06-27 | Address change (Ul. Rtm. Witolda Pileckiego 67/P.ii, 02-781, Warszawa → Ul. Marynarska 21, 02-674, Warszawa) | |
| 2018-02-21 | Name change (Apti-Medic → Aptissen Polska) | |
| 2017-09-20 | Entered in the register |
FAQ
The main business activity of Aptissen Polska focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on September 20, 2017.
The headquarters is located at: ul. Marynarska 21, 02-674 Warszawa.
The share capital of the company is PLN 50,000 (approx. $13,506).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $1,054,101, representing an increase of 11.2% compared to 2023.
No, the company recorded a net loss of $98,704 in 2024. For comparison, in 2023 the loss was $58,267, meaning the company increased its loss by 60.9%.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to $565,688 in 2024, representing 49% of all operating expenses.
Last updated: 2026-10-07